Design Therapeutics, Inc. Net Income
Design Therapeutics, Inc. (DSGN) reported Net Income of -$20.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-03
- Design Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$20.16M.
- Design Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$17.64M.
- Design Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$16.00M.
- Design Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$17.00M.
- Design Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2025 was -$69.79M.
- Design Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2024 was -$49.59M.
- Design Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2023 was -$66.86M.
- Design Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2022 was -$63.31M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$20.16M 10-Q · filed 2026-08-03 | -$37.80M 10-Q · filed 2026-08-03 | -$53.80M derived: sum of 3 quarters · filed 2026-08-03 | -$70.80M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$17.64M 10-Q · filed 2026-04-28 | -$33.63M derived: sum of 2 quarters · filed 2026-04-28 | -$50.63M derived: sum of 3 quarters · filed 2026-04-28 | -$69.71M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$32.99M derived: sum of 2 quarters · filed 2026-03-09 | -$52.08M derived: sum of 3 quarters · filed 2026-08-03 | -$69.79M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$17.00M 10-Q · filed 2025-11-05 | -$36.08M derived: sum of 2 quarters · filed 2026-08-03 | -$53.80M 10-Q · filed 2025-11-05 | -$67.45M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$19.08M 10-Q · filed 2026-08-03 | -$36.80M 10-Q · filed 2026-08-03 | -$50.45M derived: sum of 3 quarters · filed 2026-08-03 | -$63.49M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$17.71M 10-Q · filed 2026-04-28 | -$31.37M derived: sum of 2 quarters · filed 2026-04-28 | -$44.41M derived: sum of 3 quarters · filed 2026-04-28 | -$56.20M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | -$13.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$26.69M derived: sum of 2 quarters · filed 2026-03-09 | -$38.48M derived: sum of 3 quarters · filed 2026-03-09 | -$49.59M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$13.04M 10-Q · filed 2025-11-05 | -$24.83M derived: sum of 2 quarters · filed 2025-11-05 | -$35.94M 10-Q · filed 2025-11-05 | -$47.78M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$11.79M 10-Q · filed 2025-08-07 | -$22.90M 10-Q · filed 2025-08-07 | -$34.74M derived: sum of 3 quarters · filed 2025-08-07 | -$50.53M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$11.11M 10-Q · filed 2025-05-07 | -$22.95M derived: sum of 2 quarters · filed 2025-05-07 | -$38.74M derived: sum of 3 quarters · filed 2025-05-07 | -$58.67M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$11.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$27.63M derived: sum of 2 quarters · filed 2025-03-10 | -$47.57M derived: sum of 3 quarters · filed 2025-03-10 | -$66.86M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$15.79M 10-Q · filed 2024-11-07 | -$35.73M derived: sum of 2 quarters · filed 2024-11-07 | -$55.02M 10-Q · filed 2024-11-07 | -$72.36M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$19.94M 10-Q · filed 2024-08-05 | -$39.23M 10-Q · filed 2024-08-05 | -$56.57M derived: sum of 3 quarters · filed 2024-08-05 | -$74.28M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | -$19.29M 10-Q · filed 2024-05-08 | -$36.63M derived: sum of 2 quarters · filed 2024-05-08 | -$54.34M derived: sum of 3 quarters · filed 2024-05-08 | -$69.34M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$17.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$35.04M derived: sum of 2 quarters · filed 2024-03-19 | -$50.04M derived: sum of 3 quarters · filed 2024-03-19 | -$63.31M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$17.70M 10-Q · filed 2023-11-13 | -$32.70M derived: sum of 2 quarters · filed 2023-11-13 | -$45.97M 10-Q · filed 2023-11-13 | -$57.03M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$15.00M 10-Q · filed 2023-08-14 | -$28.26M 10-Q · filed 2023-08-14 | -$39.33M derived: sum of 3 quarters · filed 2023-08-14 | -$50.65M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$13.27M 10-Q · filed 2023-05-09 | -$24.33M derived: sum of 2 quarters · filed 2023-05-09 | -$35.65M derived: sum of 3 quarters · filed 2023-05-09 | -$43.28M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$11.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$22.38M derived: sum of 2 quarters · filed 2023-03-14 | -$30.02M derived: sum of 3 quarters · filed 2023-03-14 | -$35.53M 10-K · filed 2023-03-14 |
| 2021-09-30 | -$11.32M 10-Q · filed 2022-11-03 | -$18.95M derived: sum of 2 quarters · filed 2022-11-03 | -$24.47M 10-Q · filed 2022-11-03 | -$28.32M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$7.64M 10-Q · filed 2022-08-08 | -$13.15M 10-Q · filed 2022-08-08 | -$17.00M derived: sum of 3 quarters · filed 2022-08-08 | -$19.32M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$5.51M 10-Q · filed 2022-05-09 | -$9.37M derived: sum of 2 quarters · filed 2022-05-09 | -$11.69M derived: sum of 3 quarters · filed 2022-05-09 | -$13.13M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$3.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$6.17M derived: sum of 2 quarters · filed 2022-03-10 | -$7.62M derived: sum of 3 quarters · filed 2022-03-10 | -$8.28M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$2.32M 10-Q · filed 2021-11-09 | -$3.76M derived: sum of 2 quarters · filed 2021-11-09 | -$4.42M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$1.44M 10-Q · filed 2021-08-09 | -$2.10M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$663.00K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |